Literature DB >> 22882864

Hepatitis B virus/human immunodeficiency virus coinfection: interaction among human immunodeficiency virus infection, chronic hepatitis B virus infection, and host immunity.

Yi-Jia Li1, Huan-Ling Wang, Tai-Sheng Li.   

Abstract

OBJECTIVE: This review discusses progress in the studies of hepatitis B virus (HBV)/human immunodeficiency virus (HIV) coinfection and focuses on the interaction among HIV infection, chronic HBV infection, and host immunity. DATA SOURCES: Data and studies published mainly from 2008 to 2011 were selected using PubMed. STUDY SELECTION: Original articles and critical reviews concerning HBV/HIV coinfection and HBV and HIV pathogenesis were selected.
RESULTS: HIV may accelerate HBV progression by lowering CD4 count, weakening HBV-specific immunity, "enriching" HBV mutants, causing immune activation, etc. On the other hand, HBV may enhance HIV replication by activating HIV long terminal repeat (LTR) with X protein (HBX) and cause immune activation in synergy with HIV. Paradoxically, HBV may also inhibit HIV dissemination via dendritic cells.
CONCLUSIONS: The interaction among HIV, HBV, and host immunity remains poorly understood. Further research is warranted to elucidate the detailed molecular mechanisms and to translate these mechanisms into clinical practice.

Entities:  

Mesh:

Year:  2012        PMID: 22882864

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  7 in total

Review 1.  Factors Associated with the Size of HIV DNA Reservoir.

Authors:  Ni-Dan Wang; Tai-Sheng Li
Journal:  Chin Med J (Engl)       Date:  2017-01-20       Impact factor: 2.628

2.  Co-infection of syphilis and hepatitis B with carcinoma penis in a human immunodeficiency virus male.

Authors:  Balaji Govindan; Kalaivani Subramanian; Maduravasagam Karunakaran
Journal:  Indian J Sex Transm Dis AIDS       Date:  2017 Jan-Jun

3.  Combination antiretroviral therapy is associated with reduction in liver fibrosis scores in patients with HIV and HBV co-infection.

Authors:  Rongrong Yang; Xien Gui; Hengning Ke; Yong Xiong; Shicheng Gao
Journal:  AIDS Res Ther       Date:  2021-12-19       Impact factor: 2.250

4.  Computational analysis to predict functional role of hsa-miR-3065-3p as an antiviral therapeutic agent for treatment of triple infections: HCV, HIV-1, and HBV.

Authors:  Ambreen Khokhar; Samina Noorali; Muhammad Sheraz; Kuha Mahalingham; Donald G Pace; Mohammad R Khanani; Omar Bagasra
Journal:  Libyan J Med       Date:  2012-12-31       Impact factor: 1.657

5.  Biotic activity of Ca(2+)-modulating non-traditional antimicrobial and -viral agents.

Authors:  Kevin B Clark
Journal:  Front Microbiol       Date:  2013-12-12       Impact factor: 5.640

6.  Combination Antiretroviral Therapy Is Associated With Reduction in Liver Fibrosis Scores in HIV-1-Infected Subjects.

Authors:  Yijia Li; Jing Xie; Yang Han; Huanling Wang; Wei Lv; Fuping Guo; Zhifeng Qiu; Yanling Li; Shanshan Du; Xiaojing Song; Ting Zhu; Chloe L Thio; Taisheng Li
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

7.  Prevalence, risk factors and genotypes of hepatitis B infection among HIV-infected patients in the State of MS, Central Brazil.

Authors:  Solange Zacalusni Freitas; Caroline Cordeiro Soares; Tayana Serpa Ortiz Tanaka; Andréa Siqueira Campos Lindenberg; Sheila Araújo Teles; Marina Sawada Torres; Francisco Campello Amaral Mello; Maria Cássia Mendes-Corrêa; Flávia Savassi-Ribas; Ana Rita Coimbra Motta-Castro
Journal:  Braz J Infect Dis       Date:  2014-03-22       Impact factor: 3.257

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.